首页> 外文期刊>Ophthalmic Research: Journal for Research in Experimental and Clinical Ophthalmology >Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy.
【24h】

Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy.

机译:内皮素受体拮抗剂对高血压视网膜病变模型的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Hypertensive retinopathy manifests itself as progressive retinal microvascular pathology in response to aberrant blood flow. The current study sought to evaluate whether dysfunction of the vasoactive endothelin-1 (ET-1) system is involved in the pathogenesis of hypertension-induced retinopathy in an animal model of systemic hypertension. The endothelin receptor antagonist, bosentan, was administered to spontaneously hypertensive rats (SHRs) and comparisons were made with untreated SHRs and normotensive Wistar Kyoto (WKY) rats. The retinal mRNA expression of ET-1, ET-converting enzyme-1, ET(A) and ET(B) receptors and the basement membrane proteins, laminin beta1, collagen IV and fibronectin was quantified using real-time RT-PCR. In addition, retinal arteriole and/or capillary bed damage was assessed by qualitative and quantitative microscopy. mRNA for the ET(A) receptor was increased in SHRs, when compared to WKY control animals (p < 0.001). Treatment with bosentan in SHRs significantly reduced the expression of ET-1 (p < 0.05), and both the ET(A) (p < 0.0001) and ET(B) (p < 0.05) receptor subtypes. The laminin beta1, collagen IV and fibronectin mRNA expression was significantly higher in SHRs when compared to WKY control animals (p < 0.001). Treatment with bosentan abolished these responses and also the appearance of various microvascular lesions. ET-mediated vasoregulation abnormalities in the retinal microvasculature could play an associative role in lesion formation during hypertensive retinopathy.
机译:高血压性视网膜病变表现为对异常血流的反应性进行性视网膜微血管病变。当前的研究试图评估系统性高血压动物模型中血管活性内皮素-1(ET-1)系统功能异常是否与高血压诱发的视网膜病变的发病机制有关。对自发性高血压大鼠(SHR)给予内皮素受体拮抗剂波生坦,并与未治疗的SHR和血压正常的Wistar Kyoto(WKY)大鼠进行比较。使用实时RT-PCR定量ET-1,ET转换酶-1,ET(A)和ET(B)受体以及基底膜蛋白,层粘连蛋白β1,胶原IV和纤连蛋白的视网膜mRNA表达。此外,通过定性和定量显微镜评估视网膜小动脉和/或毛细血管床损害。与WKY对照动物相比,SHRs中ET(A)受体的mRNA增加了(p <0.001)。在SHRs中用波生坦治疗可显着降低ET-1(p <0.05)以及ET(A)(p <0.0001)和ET(B)(p <0.05)受体亚型的表达。与WKY对照动物相比,SHR中的层粘连蛋白beta1,胶原蛋白IV和纤连蛋白mRNA表达显着更高(p <0.001)。波生坦治疗消除了这些反应,也消除了各种微血管病变的出现。 ET介导的视网膜微脉管系统中的血管调节异常可能在高血压性视网膜病变期间的病变形成中起相关作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号